Roanna Ruiz
Stock Analyst at Leerink Partners
(0.69)
# 2,919
Out of 4,667 analysts
57
Total ratings
21.74%
Success rate
-18.08%
Average return
Main Sectors:
Stocks Rated by Roanna Ruiz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AQST Aquestive Therapeutics | Maintains: Outperform | $12 → $13 | $4.81 | +170.28% | 3 | Oct 25, 2024 | |
| SPRY ARS Pharmaceuticals | Maintains: Outperform | $21 → $25 | $13.38 | +86.85% | 3 | Sep 20, 2024 | |
| ARDX Ardelyx | Initiates: Outperform | $14 | $4.73 | +195.98% | 1 | Apr 5, 2024 | |
| UTHR United Therapeutics | Initiates: Outperform | $330 | $363.20 | -9.14% | 1 | Feb 5, 2024 | |
| CYTK Cytokinetics | Initiates: Outperform | $58 | $50.56 | +14.72% | 1 | Aug 15, 2023 | |
| CORT Corcept Therapeutics | Initiates: Market Perform | $25 | $54.46 | -54.09% | 1 | Apr 11, 2023 | |
| ENTA Enanta Pharmaceuticals | Reiterates: Market Perform | $49 | $9.32 | +425.75% | 10 | Feb 9, 2023 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $6 → $5 | $2.99 | +67.50% | 4 | Jan 27, 2023 | |
| VIR Vir Biotechnology | Maintains: Outperform | $45 → $43 | $6.85 | +527.74% | 3 | Jan 27, 2023 | |
| SCPH scPharmaceuticals | Maintains: Outperform | $12 → $13 | $3.37 | +285.76% | 7 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $6 | $3.11 | +92.93% | 6 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $20.01 | -5.02% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $120 | $84.23 | +42.48% | 3 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $75 → $50 | $19.01 | +162.96% | 7 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $3 → $2 | $0.49 | +308.66% | 6 | Oct 19, 2022 |
Aquestive Therapeutics
Oct 25, 2024
Maintains: Outperform
Price Target: $12 → $13
Current: $4.81
Upside: +170.28%
ARS Pharmaceuticals
Sep 20, 2024
Maintains: Outperform
Price Target: $21 → $25
Current: $13.38
Upside: +86.85%
Ardelyx
Apr 5, 2024
Initiates: Outperform
Price Target: $14
Current: $4.73
Upside: +195.98%
United Therapeutics
Feb 5, 2024
Initiates: Outperform
Price Target: $330
Current: $363.20
Upside: -9.14%
Cytokinetics
Aug 15, 2023
Initiates: Outperform
Price Target: $58
Current: $50.56
Upside: +14.72%
Corcept Therapeutics
Apr 11, 2023
Initiates: Market Perform
Price Target: $25
Current: $54.46
Upside: -54.09%
Enanta Pharmaceuticals
Feb 9, 2023
Reiterates: Market Perform
Price Target: $49
Current: $9.32
Upside: +425.75%
Xeris Biopharma Holdings
Jan 27, 2023
Maintains: Outperform
Price Target: $6 → $5
Current: $2.99
Upside: +67.50%
Vir Biotechnology
Jan 27, 2023
Maintains: Outperform
Price Target: $45 → $43
Current: $6.85
Upside: +527.74%
scPharmaceuticals
Jan 27, 2023
Maintains: Outperform
Price Target: $12 → $13
Current: $3.37
Upside: +285.76%
Jan 27, 2023
Maintains: Market Perform
Price Target: $8 → $6
Current: $3.11
Upside: +92.93%
Dec 20, 2022
Initiates: Outperform
Price Target: $19
Current: $20.01
Upside: -5.02%
Nov 15, 2022
Maintains: Outperform
Price Target: $110 → $120
Current: $84.23
Upside: +42.48%
Nov 3, 2022
Maintains: Market Perform
Price Target: $75 → $50
Current: $19.01
Upside: +162.96%
Oct 19, 2022
Maintains: Market Perform
Price Target: $3 → $2
Current: $0.49
Upside: +308.66%